c-Jun Promotes whereas JunB Inhibits Epidermal Neoplasia  by Jin, Jane Y. et al.
c-Jun Promotes whereas JunB Inhibits Epidermal
Neoplasia
Jane Y. Jin1, Hengning Ke1, Russell P. Hall1 and Jennifer Y. Zhang1
Deregulation of the activator protein 1 (AP1) family gene regulators has been implicated in a wide range of
diseases, including cancer. In this study we report that c-Jun was activated in human squamous cell carcinoma
(SCC) and coexpression of c-Jun with oncogenic Ras was sufficient to transform primary human epidermal
cells into malignancy in a regenerated human skin grafting model. In contrast, JunB was not induced in a
majority of human SCC cells. Moreover, exogenous expression of JunB inhibited tumorigenesis driven by Ras
or spontaneous human SCC cells. Conversely, the dominant-negative JunB mutant (DNJunB) promoted
tumorigenesis, which is in contrast to the tumor-suppressor function of the corresponding c-Jun mutant. At the
cellular level, JunB induced epidermal cell senescence and slowed cell growth in a cell-autonomous manner.
Consistently, coexpression of JunB and Ras induced premature epidermal differentiation concomitant with
upregulation of p16 and filaggrin and downregulation of cyclin D1 and cyclin-dependent kinase 4 (CDK4). These
findings indicate that JunB and c-Jun differentially regulate cell growth and differentiation and induce opposite
effects on epidermal neoplasia.
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INTRODUCTION
JunB and c-Jun, along with JunD and Fos group proteins
(c-fos, FosB, Fra1, and Fra2), comprise the core members of
the activator protein 1 (AP1) family of transcription factors.
These proteins share common structural and functional motifs
that include a transactivation (TA) domain for regulating
target gene transcription, an amphipathic leucine zipper
(bZIP) domain for protein dimerization, and a basic domain
for DNA binding (Eckert et al., 1997; Angel et al., 2001;
Jochum et al., 2001; Eferl and Wagner, 2003). Recent mouse
genetic studies have demonstrated that AP1 has key roles in
regulating a wide spectrum of biological processes, including
embryonic development, tissue homeostasis, tumorigenesis,
and inflammation (Angel et al., 2001; Jochum et al., 2001;
Eferl and Wagner, 2003; Hess et al., 2004). On the other
hand, different AP1 proteins display structural and functional
differences. For example, both JunB and c-Jun contain a c-Jun
N-terminal kinase (JNK)-docking site, but only c-Jun has a
typical JNK-phosphorylation site in the TA domain. Thus,
JunB is not activated by JNK in the same manner as c-Jun, and
is often recognized as an inhibitor to target gene expres-
sion (Chiu et al., 1989; Deng and Karin, 1993). However, the
latter notion has been recently challenged by the findings
demonstrating that each AP1 subunit can either induce or
suppress gene expression in a cell context- and target gene-
dependent manner (Chinenov and Kerppola, 2001; Hess
et al., 2004).
In the skin, AP1 subunits are expressed in a species-
specific pattern and are implicated in the specification of
temporal and spatial patterns of gene expression during
terminal differentiation of keratinocytes and the manifestation
of inflammatory responses (Basset-Seguin et al., 1990;
Briata et al., 1993; Welter and Eckert, 1995; Mehic et al.,
2005). Of particular interest, mice with epidermal-
specific deletion of JunB (JunBepi/) or both JunB and c-Jun
(JunBepi/c-Junepi/) are born alive with no obvious skin
defects; but within a few weeks after birth, these mice
develop bone and inflammatory skin abnormalities resem-
bling arthritic and psoriatic responses in humans (Zenz et al.,
2005; Meixner et al., 2008). Moreover, JunBepi/ but not
c-Junepi/ mice exhibit defects in hematopoiesis, kidney,
and lymph node organogenesis (Zenz et al., 2005). These
findings underscore that JunB and c-Jun have overlapping yet
differential roles in regulating mouse epidermal homeostasis
and can act in the epidermis to control systemic well-being.
AP1 has been generally characterized as a dominant
promoter of skin cancer. AP1 inhibition through multiple
genetic approaches, including epidermal expression of the
dominant-negative mutant of c-Jun (DNc-Jun, also known as
TAM67) in transgenic mice or genetic deletion of either c-Jun
or c-fos, suppresses murine skin carcinogenesis induced by
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chemicals, UV radiation, or viral oncogenes (Saez et al., 1995;
Jochum et al., 2001; Thompson et al., 2002; Young et al., 2002;
Cooper et al., 2003; Dhar et al., 2004; Zhang et al., 2007).
In addition, expression of DNc-Jun inhibits tumorigenesis of
murine squamous cell carcinoma (SCC) cell lines in nude mice
(Domann et al., 1994). Conversely, AP1 activation by upstream
MKK7 (mitogen-activated protein kinase kinase 7)/JNK signaling
cascade is sufficient to couple with oncogenic Ras to induce
human epidermal malignancy (Zhang et al., 2007). Similarly,
overexpression of JunB enhances the malignant phenotype of
transformed rat keratinocytes in vitro (Bernstein and Colburn,
1989). In addition, JunB mRNA is upregulated in advanced
skin cancers induced by the 7,12-dimethyl benz[a] anthracene/
12-o-tetradecanoyl phorbol-13-acetate carcinogenesis protocol
(Schlingemann et al., 2003), although it is unclear whether
the increased JunB expression is involved in the malignant
progression or is a secondary response to tumor advance-
ment. Taken together, these findings indicate that AP1 has a
dominant role in epidermal tumorigenesis. On the other
hand, JunB has been identified as a key regulator respon-
sible for the resistance of JB6() mouse SCC cells to tumor
promotion and the suppression of B9(SQ) mouse SCC cells
to epithelial-to-mesenchymal transition (Hulboy et al., 2001;
Finch et al., 2002), which pinpoints JunB as a tumor
suppressor. These controversial findings imply that JunB
functions in a species- or cell context-specific manner. Such
possibility has been shown in the lymphoid system where
JunB inhibits transformation of B cells but not T cells
(Szremska et al., 2003). Thus, it is essential to examine the
role of Jun proteins directly in human SCC.
In this study, we took advantage of using the human SCC
model regenerated on immunodeficient mice and the
spontaneous human SCC samples to determine how JunB
and c-Jun were involved in regulating epidermal growth and
neoplasia. We found that c-Jun activation was relevant to
human SCC and was sufficient to couple with oncogenic Ras
to transform normal epidermal cells into malignancy. In
contrast, JunB inhibited epidermal tumorigenesis driven by
defined genetic changes and spontaneous human SCC cells.
Conversely, the dominant-negative JunB mutant (DNJunB)
promoted neoplasia. At the cellular level, JunB induced
epidermal senescence and differentiation, which was accom-
panied with an upregulation of the cell cycle inhibitor p16
and the differentiation marker filaggrin and a downregulation
of cell cycle promoter cyclin-dependent kinase 4 (CDK4).
Our findings indicate that JunB and c-Jun have opposite roles
in human epidermal neoplasia and that their functional
specificities are dependent on both N- and C-terminal domains.
RESULTS
JunB and c-Jun are differentially induced in human SCC
To determine the clinical relevance of JunB and c-Jun, we first
examined their expression status in human SCC. By
immunostaining, we found that both JunB and c-Jun were
expressed in almost all layers of normal human epidermis
and displayed both cytoplasmic and nuclei localization
(Figure 1a and b), as described in previous studies (Welter
and Eckert, 1995; Mehic et al., 2005). In SCC samples, c-Jun
was detected primarily in the nuclei of the bulk of cancer
cells. In contrast, JunB was present in the nuclei of a limited
number of cells on the tumor tissues (Figure 1a–c). In
agreement with these data, immunoblotting showed that
c-Jun was highly activated in A431, a human SCC cell line, as
indicated by the increased levels of phosphorylated c-Jun
when compared with normal human keratinocytes (Figure
1d). Similarly, phosphorylated c-Jun was increased in a
majority of SCC samples when compared with the normal
skin. In contrast, JunB and p-JunB were expressed at lower
levels in A431 cells than they were in normal keratinocytes.
In addition, despite the increased levels of p-JunB in SCC, the
total levels of JunB were significantly reduced in 6 out of the
10 SCC tissues examined (Figure 1d). These data indicate that
c-Jun is activated whereas JunB is reduced in human SCC,
underscoring a clinical relevance of these proteins to human
SCC.
c-Jun promotes whereas JunB inhibits epidermal neoplasia
To determine whether Jun proteins have primary roles in the
pathogenesis of epidermal neoplasia, we first tested their
gain-of-function effects on the Ras-driven human SCC model
(Dajee et al., 2003). To do this, primary human epidermal
cells were isolated from normal human skin and transduced
with retroviruses for expression of the oncogenic Ras along
with JunB or c-Jun. These cells were then seeded onto pieces
of devitalized and split-thickness human dermis for human
skin regeneration on SCID (severe combined immunodefi-
cient) mice. The skin grafts were collected at 6 weeks
postgrafting and were confirmed to express the transduced
genes by immunostaining (Supplementary Figure S1a online).
Interestingly, the grafts expressing Ras and c-Jun developed
features of epidermal malignancy with resemblance to
human SCC. These tissues lacked a clear tissue boundary
between dermal and epidermal compartments and were
hyperproliferative as indicated by the disordered histological
appearances and the abundance of Ki-67-positive cells
(Figure 2a and b), respectively. In addition, they expressed
high levels of cytokeratin 8 (Figure 2c), a simple epithelial
marker detected in malignant SCC (Watanabe et al., 1995).
Moreover, vimentin, a mesenchymal cell marker, was highly
expressed in these tissues, whereas filaggrin, a late epidermal
differentiation marker, was nearly absent in them (Figure 2d
and e), which indicate that these tumors have undergone
epithelial–mesenchymal transition but not differentiation. In
contrast, the grafts expressing Ras and JunB appeared normal
as judged by the delineated tissue boundary and the basal
layer-confined cell proliferation, as well as the absence of
vimentin and cytokeratin 8 and the presence of filaggrin
(Figure 2a–e). Thus, c-Jun but not JunB is able to act in
synergy with Ras to induce epidermal tumorigenesis.
To further test the differential effects of Jun proteins on SCC,
we transfected A431 cells for expression of JunB-ER (estrogen
receptor) and c-Jun-ER. These fusion proteins have been
previously validated to be functionally inducible by exogenous
4-hydroxytomoxifen (4-OHT) (Fialka et al., 1996; Andrecht
et al., 2002). We then performed soft agar colony formation,
an assay commonly used to assess anchorage-independent
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cell growth of cancer cells. We found that cells expressing
JunB-ER developed a reduced number of soft agar colonies in
response to 4-OHT treatment. In contrast, cells expressing
c-Jun-ER developed an increased number of colonies follow-
ing 4-OHT induction (Figure 2f). These findings confirm that
JunB and c-Jun have opposite effects on human SCC, with
JunB acting as an inhibitor for tumorigenesis.
JunB suppression of tumorigenesis requires its TA domain
Previous studies have shown that JunB and c-Jun inhibit and
promote mouse embryonic cell proliferation, respectively.
Their distinctive effects on cell growth have been attributed to
the differences in their TA domains, such that c-Jun displays a
higher transcriptional activity than JunB (Chiu et al., 1989;
Shaulian and Karin, 2001). Like DNc-Jun, which lacks a TA
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Figure 1. c-Jun but not JunB is induced in human squamous cell carcinoma (SCC). (a, b) Immunostaining of (a) c-Jun and (b) JunB in normal human
skin (NS) and representative patient SCC samples. c-Jun and JunB (orange); nuclei (blue, Hoechst 3342); scale bar¼40 mm. (c) Percentage of cells with positive
nuclei staining for c-Jun and JunB in NS and SCC samples. The graph represents cell counts from 4 to 5 sections of NS or SCC þ SD. (d) Immunoblotting for
c-Jun, phosphorylated c-Jun (p-c-Jun), JunB, p-JunB, and actin with protein lysates isolated from human keratinocytes (KC), A431 SCC cells, NS, or 10 SCC
samples. Semiquantitative densitometry was analyzed using Kodak imaging system (Rochester, NY) and the number shown below each band represents the
relative reading units obtained by normalizing the reading of each band to that of actin of the same sample and then to the normalized number of keratinocytes
or NS. Please note the samples shown in a, b, and d were from different patients.
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domain and functions as a dominant-negative c-Jun mutant
(Brown et al., 1993), DNJunB, the corresponding JunB
mutant, induced a dominant-negative effect when tested
by AP1-luciferase gene reporter assay (Ikebe et al., 2007)
(Figure 3a). We predicted that if the functional divergence
between JunB and c-Jun was caused by the differences in
their TA domains, DNJunB and DNc-Jun would induce
similar effects on epidermal cell growth and neoplasia.
DNc-Jun has been previously shown to inhibit tumorigenesis
in both mouse and human skin tumor models (Domann et al.,
1994; Jochum et al., 2001; Thompson et al., 2002; Young
et al., 2002; Cooper et al., 2003; Dhar et al., 2004; Zhang
et al., 2007). To determine DNJunB effects on human
SCC, we used a previously established human SCC model,
in which coexpression of Ras and MKK7, an upstream
activator of AP1, transforms normal human epidermal cells
into malignancy (Zhang et al., 2007). We transduced primary
human keratinocytes for expression of Ras and MKK7 along
with JunB or DNJunB and then used these cells for skin
regeneration on immunodeficient mice. Expression of the
transduced genes, including Ras, MKK7, JunB, and DNJunB,
were confirmed by immunostaining of the regenerated skin
tissues (Supplementary Figure S1b online). In line with the
inhibitory effect of JunB on A431 cells, the grafts expressing
Ras, MKK7, and JunB appeared normal with an intact tissue
boundary and basal cell-confined cell proliferation (Figure 3b
and c). They displayed negative detection of cytokeratin 8
and vimentin and positive detection of filaggrin (Figure 3d–f).
In contrast, the grafts expressing Ras, MKK7, and DNJunB
developed malignant features similar to those observed in
tissues expressing Ras and c-Jun. These features include
tissue invasion, abnormal cell proliferation, and epithelial–
mesenchymal transition, as indicated by the appearance of
disrupted tissue boundaries, the high numbers of Ki-67-
positive cells, and the abundant expression of cytokeratin 8
and vimentin but not filaggrin (Figure 3b–f). These data
indicate that DNJunB does not inhibit tumorigenesis driven
by Ras and MKK7, which lead us to predict that DNJunB
might be sufficient by itself to promote Ras-driven tumor-
igenesis. Consistent with this idea, the grafts expressing
Ras and DNJunB displayed invasive tumor growth in a
manner similar to those expressing Ras, MKK7, and DNJunB
(Figure 3b–f). Furthermore, both DNJunB and c-Jun are
sufficient to support subcutaneous tumor growth when
coupled with Ras (Supplementary Figure S2 online). These
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Figure 2. JunB and c-Jun display opposite roles in Ras-driven epidermal
neoplasia. (a) Histological appearances of 6-week-old skin grafts regenerated
on severe combined immunodeficient (SCID) mice. Primary human
keratinocytes were transduced to express genes as indicated on the upright
corner of each image and then used for skin grafting. D, dermis; E, epidermal
tissue; H&E, hematoxylin and eosin; M, muscle; V, blood vessel. Grafts
(n¼4–6) displayed 100% phenotypic penetrance. (b–e) Immunofluorescent
staining for Ki-67, cytokeratin 8 (K8), vimentin, and filaggrin (orange); nuclei
(blue, Hoechst 3342); scale bar¼ 40mm. (f) Soft agar colony formation. A431
cells transduced for expression of LacZ control, JunB-ER, or c-Jun-ER were
used for soft agar colony formation in the absence or presence of 100 nM
4-hydroxy-tamoxifen (4-OHT). The average numbers of colonies from
triplicate wells þ SD are shown.
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data indicate that contrary to DNc-Jun, DNJunB promotes
Ras-driven tumorigenesis. Thus, the N-terminal TA domain
of JunB is required for its inhibitory effect on epidermal
tumorigenesis whereas its C-terminus is actively involved in
promoting tumorigenesis.
JunB induces cell growth inhibition
Cancer is a result of abnormal activities of multiple
oncogenes and/or tumor suppressors. Of particular relevance,
activation of oncogenic Ras alone induces epidermal cell
growth arrest and senescence (Dajee et al., 2003). Therefore,
additional molecular changes, such as JNK activation or
NF-kB blockade, are required to overcome Ras-induced cell
growth arrest and senescence; and as a result, JNK activation
or NF-kB blockade is necessary to act in concert with Ras to
transform normal epidermal cells into malignancy (Dajee
et al., 2003; Zhang et al., 2007; Ke et al., 2010). The inability
of JunB in promoting Ras-driven tumorigenesis led us to
predict that JunB is not able to surmount Ras-induced cell
growth arrest. Consistent with this idea, keratinocytes
expressing JunB grew slower than green fluorescent protein
(GFP)-control cells when cultured either in separate dishes or
in co-cultures (Figure 4a), which indicates that JunB inhibits
epidermal cell growth in a cell-autonomous fashion. Simi-
larly, JunB-ER induced a cell growth inhibition in a 4-OHT
dose-response manner (Figure 4b), further confirming that the
inhibitory effect on cell growth is a result of JunB function. In
addition, induction of JunB-ER with 4-OHT increased cell
senescence as indicated by the increased number of cells
positive in b-galactosidase (Figure 4c and d). Further cell
cycle analysis by flow cytometry showed that keratinocytes
transduced to express JunB were less efficient in entering S
phase than control cells (Figure 4e). Consistent with these
in vitro data, the core G1/S-phase cell cycle promoters,
including cyclin D1 and CDK4, were downregulated in
tissues expressing JunB and Ras either with or without MKK7,
whereas the cell cycle inhibitor p16 was upregulated in these
tissues. On the contrary, cyclin D1 and CDK4 were increased
and p16 was decreased in the tumor tissues expressing Ras
and c-Jun or DNJunB (Figure 4f). These data indicate that
JunB inhibits human epidermal cell growth in a cell-
autonomous fashion and is unable to overcome Ras-induced
cell growth inhibition.
DISCUSSION
Cancer is a result of genetic changes leading to gain-of-
function of classical oncogenes and/or loss-of-function of
tumor suppressors. However, a single genetic change is
usually not sufficient to induce tumor growth, which is
exemplified by the fact that oncogenic Ras induces epidermal
cell senescence (Dajee et al., 2003). Abnormal induction or
suppression of other key molecules because of genetic,
epigenetic or environmental perturbations is therefore essen-
tial in the malignant transform of cells harboring one or more
oncogenic mutations. Here, we showed that c-Jun was able
to act in synergy with oncogenic Ras to transform normal
epidermal cells into malignancy. In contrast, JunB not only
failed to couple with Ras but also inhibited tumorigenesis
induced by coexpression of Ras and MKK7. Most interest-
ingly, the JunB mutant missing the TA-domain is a potent
promoter of epidermal malignancy, which is in sharp contrast
to the tumor inhibitory effect of the corresponding c-Jun
mutant. Our findings indicate that the functional differences
between JunB and c-Jun are not simply determined by the
differential transactivation potential of their N-terminal TA-
domains, as indicated by previous studies (Chiu et al., 1989;
Shaulian and Karin, 2001). Their c-terminal domains are also
functionally distinct, which is consistent with the biochem-
ical data demonstrating that these domains are involved in
governing the specificity of target gene recognition and
transcriptional regulation (Deng and Karin, 1993).
The functional differences between JunB and c-Jun are
multifaceted and are in part manifested in their effects on cell
growth and differentiation. JunB induced epidermal growth
inhibition, yet cells expressing both JunB and Ras were able
to generate live but non-invasive skin grafts. This is surprising
because Ras inhibited epidermal cell growth and differentia-
tion; and consequently cells transduced to express Ras alone
were not able to produce live skin grafts (Dajee et al., 2002;
Lazarov et al., 2002). Presumably, JunB overcomes Ras-
inhibition of differentiation and thereby prevented skin graft
failure. Interestingly, we observed that c-Jun did not increase
cell proliferation of normal epidermal cells (data not shown).
Yet, coexpression of c-Jun with Ras induced invasive
epidermal tumor growth accompanied with the deficiency
of terminal tissue differentiation and the occurrence of
epithelial-mesenchymal transition as evidenced by the
negative and positive detection of filaggrin and vimentin,
respectively. The invasive phenotype induced by c-Jun and
Ras is consistent with a previous study demonstrating that
c-Jun promoted mouse SCC growth through induction of
matrix metalloproteinase-2 and -9 expression (Zhang et al.,
2006). In contrast to normal keratinocytes, human SCC cells
are responsive to c-Jun induction by showing an increase in
soft agar colony formation. These findings indicate that c-Jun
acts synergistically with other oncogenes, such as Ras, to
induce invasive epidermal growth.
JunB is able to substitute c-Jun during embryonic devel-
opment (Passegue et al., 2002), indicating that Jun proteins
have redundant roles in embryogenesis. Similarly, our
findings implicate that JunB and c-Jun are both involved in
epidermal stratification, which is in agreement with a recent
report demonstrating that mice with expression of the
dominant-negative c-Jun mutant in the superbasal layer of
epidermis had defects in epidermal differentiation and were
resistance to tumor induction (Rorke et al., 2010). However,
the molecular mechanisms governing the functional antag-
onism or synergism between JunB and c-Jun are yet to
be defined. On this regard, JunB appears to inhibit c-Jun
activation, as indicated by the cytoplasmic localization of
c-Jun in tissues expressing Ras and JunB (Supplementary
Figure S1a-b online) and its nuclei presence in the tumor
tissues expressing Ras and DNJunB (Supplementary Figure
S1b online). Of further interest, Ras-inhibition of epidermal
stratification is dependent on the PI3K signaling path-
way (Dajee et al., 2002). It is not clear whether Jun proteins
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cross-talk with the PI3K pathway to overcome the differentia-
tion defect.
Consistent with the findings obtained with the experi-
mental models of human SCC, JunB is reduced at the protein
level in some primary human SCC samples. In contrast, c-Jun
is highly expressed and activated in SCC, which is consistent
with our previous data demonstrating that JNK activation is
increased in a majority of human SCC (Zhang et al., 2007;
Ke et al., 2010). Thus, JunB loss-of-function and c-Jun gain-of-
function are both clinically relevant to human SCC. However,
it is worth noting that both c-Jun and JunB genes were shown
to be downregulated in well-differentiated locally invasive
SCC at the mRNA levels (Haider et al., 2006). The down-
regulation of JunB mRNA is consistent with the reduced JunB
activity as detected by immunostaining. The discrepancies
between the mRNA and protein levels of c-Jun suggest that
c-Jun is subject to regulation at a post-translational level
in human SCC. Of further interest, JunB phosphorylation has
been linked to both transcriptional activation and protein
degradation (Li et al., 1999; Bakiri et al., 2000). The functional
relevance of the positive detection of pJunB in SCC has yet to
be investigated. Overall, findings to date establish a dominant
role for MKK7/JNK/c-Jun signaling axis and a tumor-suppressor
role for JunB in human SCC. The findings of this study
underscore the importance of distinguishing different AP1
subunits in future therapeutic designs.
MATERIALS AND METHODS
Cell culture, gene transfer, and gene reporter assay
Complementary DNAs encoding c-Jun, JunB, and the N-terminal
deletion mutant of JunB were subcloned into the LZRS retroviral
vector (Treier et al., 1995; Ikebe et al., 2007). Viral production and
infection of human keratinocytes were performed as described
(Robbins et al., 2001). Primary human keratinocytes were isolated
from neonatal foreskin and cultured in keratinocyte serum-free
media (Invitrogen Corporation, Carlsbad, CA). At 1 day before viral
infection, early passage (passages 1 and 2) keratinocytes were plated
at 5 105 and 3 104 cells per 10 cm or 35mm dishes, respectively.
Protein expression was confirmed by immunoblotting with protein
lysates collected 2 days after gene transduction. Dural-luciferase
gene reporter assays were performed in 293T cells as described
(Zhang et al., 2005). Relative luciferase unit was obtained by
normalizing the firefly luciferase reading unit to that of the internal
Renilla luciferase control and then to the normalized numbers of
LacZ control cells.
Cell growth, flow cytometry, and soft agar colony formation
For growth analysis, keratinocytes were infected as described above
and trypsinized for cell counting 3 days postinfection. For co-culture
cell growth analysis, keratinocytes transduced to express GFP or
JunB were trypsinized 1 day postinfection and equal numbers of
GFP- and JunB-expressing cells were mixed for subculture. Cells
were then trypsinized 72 hours later and counted under immuno-
fluorescent microscope for GFP-positive and GFP-negative cells. For
cell cycle analysis, trypsinized cells were fixed in cold 70% ethanol
for 24 hours and treated with 100mgml–1 DNase-free ribonuclease
(Sigma, St Louis, MO) at room temperature for 10minutes. Cells
were then stained with propidium iodide (50 mgml–1 in phosphate-
buffered saline; Sigma) right before flow cytometry analysis (Duke
Flow Cytometry Core Facility). A431 cells (ATCC, Manassas, VA)
were cultured in 10% fetal bovine serum/DMEM, and transfected
with the pUbi-JunB-ER or pMV7c-Jun-ER fusion constructs using
GenJet Plus reagent (SignaGen Laboratories, Ijamsville, MD)
(Fialka et al., 1996; Andrecht et al., 2002). Cells were then used
for growth and soft agar colony formation analysis as described
(Ke et al., 2010).
Animal studies
Animal studies were conducted in accordance with protocols
approved by the Duke Animal Care and Use Committee.
CB.17.SCID mice were purchased from the National Cancer Center,
and human skin regeneration was performed as described
(Dajee et al., 2003; Zhang et al., 2007). Briefly, primary human
keratinocytes were transduced with retrovirus for expression of the
interested genes and seeded onto 1 cm2 devitalized human cadaver
dermis (National Disease Research Institute, Philadelphia, PA).
When cells reached confluence, the dermis was lifted from tissue
culture plate and grafted onto the back of mice. Regenerated human
tissue samples were analyzed at 6 weeks postgrafting. Data shown
represent two sets of independently grafted animals with three
animals per group. Phenotypic penetrance was observed in all
animals with successful grafts.
b-Galactosidase staining
Primary human keratinocytes were mock transduced or transduced
with retroviruses encoding JunB-ER. At 1 day post-transfection,
cells were treated with 100 nM 4-OHT for 48 hours and then fixed in
methanol followed by staining for the senescence-associated
acidic b-galactosidase (Cell Signaling Technology, Danvers, MA).
Blue cells and non-blue cells were counted on photographed
microscopic images (n¼ 10) taken under Olympia BX41 micro-
scopic imaging system (Center Valley, PA).
Immunoblotting and immunohistology
Antibodies against phosphorylated c-Jun, c-Jun, JunB, p-JunB, Actin,
CDK4, filaggrin, and ERa were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA), and the antibody against p16 was
from Genescript (Piscataway, NJ). For immunoblotting, protein
lysates (20 mg each samples) isolated from surgically discarded
human skin, SCC samples or cultured cells were separated on 12%
Figure 3. Dominant-negative JunB mutant (DNJunB) promotes Ras-driven epidermal neoplasia. (a) Activator protein 1 (AP1) gene reporter assay.
293T cells were co-transfected with an AP1-luciferase gene reporter construct along with expression constructs encoding LacZ, c-Fos, DNJunB, or DNc-Jun.
The graph represents means of relative luciferase reading units (RLU)þ SD. (b) Histological appearances of skin grafts regenerated on severe combined
immunodeficient (SCID) mice with primary human keratinocytes that have been transduced to express genes as indicated on the upper left corner of each image.
D, dermis; E, epidermal tissue; H&E, hematoxylin and eosin; M, muscle; MKK7, mitogen-activated protein kinase kinase 7; V, blood vessel. Grafts (n¼ 4–6)
displayed 100% phenotypic penetrance. (c–f) Immunofluorescent staining for Ki-67, cytokeratin 8, vimentin, and filaggrin (orange); nuclei
(blue, Hoechst 3342); scale bar¼ 40mm.
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SDS-PAGE gel. For hematoxylin and eosin staining, tissue samples
were fixed in 10% formalin and then embedded in paraffin blocks
for tissue sectioning and staining in Duke Pathology Laboratory. For
immunofluorescent staining, frozen tissue sections were fixed with
100% methanol, incubated with primary antibodies against Ki-67
(Labvision, Fremont, CA), CDK4, filaggrin, or p16 and then detected
Separate culture Co-culture
16
N
o.
 
o
f c
el
ls 
(×1
0,
00
0)
N
o.
 
o
f c
el
ls 
(×1
0,
00
0)
N
o.
 
o
f c
el
ls 
(×1
0,
00
0)
12
8
8
4
4
0 0
GFP JunB GFP JunB
12
10
8
6
4
2
0
4-OHT(nM) 10
00 5 10
Con JunB-ER
20 40 80 10
00
Con – 4-OHT Con + 4-OHT
β-Gal β-Gal
β-Gal β-Gal
JunB-ER – 4-OHT JunB-ER + 4-OHT
40
40
60
8030
20
20
Pe
rc
e
n
ta
ge
 o
f β
-
G
al
 (+
)
ce
lls
Pe
rc
e
n
ta
ge
 o
f c
el
ls
10
0
0
–
+ 4-OHT
Con
Con
– –+ +
JunB-ER
JunB-ER
4-OHT
Nonspecific
JunB-ER
Actin
GFP
JunB
G0/G1 S M
CDK4
Cyclin D1 Cyclin D1 Cyclin D1 Cyclin D1
p16p16p16p16 p16
CDK4 CDK4 CDK4 CDK4
Cyclin D1
Ras, c-Jun Ras, JunB Ras, MKK7, JunB Ras, MKK7, DNJunB Ras, DNJunB
Ras, c-Jun Ras, JunB Ras, MKK7, JunB Ras, MKK7, DNJunB Ras, DNJunB
Ras, c-Jun Ras, JunB Ras, MKK7, JunB Ras, MKK7, DNJunB Ras, DNJunB
Figure 4. JunB inhibits human epidermal cell growth and increases cell senescence. (a) Cell growth analysis. Primary human keratinocytes were
transduced with retroviruses for expression of green fluorescent protein (GFP) or JunB and then plated in triplicates in separate or co-culture dishes. GFP-positive
and GFP-negative cells were trypsinized and counted under microscope 72hours later. (b) Cell growth analysis. Keratinocytes transduced to express LacZ or
JunB-ER were plated in triplicates in the presence of 4-hydroxytomoxifen (4-OHT) in a dose-response manner and then collected for cell counting 72 hours
later. (c) Cell senescence analysis. Mock-transduced control (Con) cells and cells expressing JunB-ER were treated with 100 nM 4-OHT for 48 hours and then
processed for b-galactosidase staining (b-Gal, blue); scale bar¼ 100mm. Inducible expression of JunB-ER was confirmed by immunoblotting with an
antibody against ERa with actin for control. (d) Quantitative index of b-Gal-positive cells. (e) Cell cycle distribution analysis by flow cytometry of keratinocytes
transduced to express GFP or JunB. (f) Immunofluorescent staining of the regenerated skin grafts with antibodies against cyclin D1, cyclin-dependent kinase 4
(CDK4), and p16 (orange); nuclei (blue, Hoechst 3342); scale bar¼40 mm. Graphs in a, b, d, and e represent the mean valuesþ SD.
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with a secondary antibody conjugated to Alexa688 (Invitrogen).
Sections were counterstained with 1 mgml–1 Hoechst. Pictures were
taken under Olympia BX41 microscopic imaging system.
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